Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;18(4):211-213.
doi: 10.1038/s41575-021-00420-w.

SARS-CoV-2 vaccination in IBD: more pros than cons

Ferdinando D'Amico  1   2 , Christian Rabaud  3 , Laurent Peyrin-Biroulet  4 , Silvio Danese  5   6
Affiliations

SARS-CoV-2 vaccination in IBD: more pros than cons

Ferdinando D'Amico et al. Nat Rev Gastroenterol Hepatol. 2021 Apr.

Abstract

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.

PubMed Disclaimer

Conflict of interest statement

L.P.-B. has served as a speaker, consultant and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, H.A.C. Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma, Celgene, Biogen, Lycera, Samsung Bioepis and Theravance. S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. The remaining authors declare no competing interests.

References

    1. D’Amico F, Danese S, Peyrin-Biroulet L. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2020;18:2689–2700. - PMC - PubMed
    1. Piovani D, et al. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019;157:647–659.e4. doi: 10.1053/j.gastro.2019.04.016. - DOI - PubMed
    1. Melmed GY, Rubin DT, McGovern DPB. Winter is coming! Clinical, immunological, and practical considerations for vaccinating patients with IBD during the COVID pandemic. Gastroenterology. 2020 doi: 10.1053/j.gastro.2020.10.013. - DOI - PMC - PubMed
    1. Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Rahier JF, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis. 2014;8:443–468. doi: 10.1016/j.crohns.2013.12.013. - DOI - PubMed

MeSH terms